Pre-Conference Focus Day

Tuesday, May 13, 2025

8:00 am Check-In & Light Breakfast

8:55 am Chair’s Opening Remarks

  • Mark Osterman Vice President, Early Differentiation and Pipeline for Immunology, Cardiovascular, and Neuroscience, Bristol Myers Squibb

Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes

9:00 am Harnessing Novel AI & ML Tools to Revolutionize Patient Diagnostics for Unparalleled Personalized Therapy Opportunities

  • Steven Levitte Medical Director - Product Development, Gastroenterology Hepatology & Metabolism, Genentech

Synopsis

• Leveraging AI-driven algorithms for standardized ME score calculation and enhancing efficiency in clinical trial operations

• The potential for AI to streamline trial endpoints and address screen failures in IBD studies

• Exploring regulatory challenges and the need for cross-industry collaboration to advance AI and CDx adoption

9:30 am Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling

  • Joerg Heyer Head of Translational Science and Medicine, Palisade Bio

Synopsis

• Utilizing AI to refine patient subtypes based on molecular and clinical profiles

• Enhancing therapeutic targeting by bridging IBD heterogeneity gaps

• Discovering hidden subgroups to drive better therapy alignment

10:00 am Morning Networking Break

Harnessing AI & Data Integration to Optimize Combination Therapies & Enhance Predictive Accuracy in IBD Care

11:00 am Optimizing Drug Combination Strategies with AI Insights to Enhance Efficacy & Minimize Risks in IBD Treatment

  • Vinayagam Arunachalam Director & Head, Computational & Systems Biology, Early Clinical Development, GI2-TAU, Takeda Pharmaceutical

Synopsis

• Predicting optimal drug combinations for better patient outcomes

• Minimizing adverse events by refining combination therapy strategies

• Enhancing therapeutic synergies through data-informed drug pairings

11:30 am Rountable Discussion: Revolutionizing Data Integration & Processing Pipelines to Maximize AI-Powered Predictive Accuracy in IBD Care

  • Mark Osterman Vice President, Early Differentiation and Pipeline for Immunology, Cardiovascular, and Neuroscience, Bristol Myers Squibb

Synopsis

• How can pipelines be streamlined to integrate diverse patient datasets?

• Enhancing predictive accuracy by reducing noise in data processing

• Improving patient outcomes by leveraging advanced analytics

12:30 pm Lunch Break & Networking

Leveraging Digital Pathology & Spatial Transcriptomics to Unlock Deeper Molecular Insights & Drive Precision Care in Crohn’s & Colitis

1:30 pm Integrating Spatial Biology & Digital Pathology to Reveal Hidden Patterns & Revolutionize IBD Therapeutics

  • Gerard Honig Associate Director, Biomarker Research, Otsuka

Synopsis

• Combining digital pathology and spatial transcriptomics for better stratification

• Can biopharma identify actionable molecular targets through spatial mapping?

• Driving therapeutic innovations using integrated molecular insights

2:00 pm Rountable Discussion: Overcoming IBD Heterogeneity with AI-Driven Digital Pathology & Radiology to Optimize Patient Subtyping & Outcomes

Synopsis

• AI to refine patient subtypes based on molecular and clinical profiles

• Enhancing therapeutic targeting by bridging IBD heterogeneity gaps

• Discovering hidden subgroups to drive better therapy alignmen

2:30 pm Afternoon Networking Break

Advancing in Non-Invasive Imaging Technologies to Optimize Patient Monitoring & Treatment Strategies in IBD

3:30 pm Using Ultrasound to Non-Invasively Monitor Patient Progress for Enhanced Clinical Decision Making

Synopsis

• Exploring the use of ultrasound for real-time, non-invasive assessment of therapeutic efficacy in preclinical and clinical settings

• Investigating the role of advanced imaging biomarkers to inform and refine drug development strategies

• Integrating ultrasound technologies into longitudinal monitoring frameworks to improve patient stratification and treatment optimization

4:00 pm Applying Novel Imaging Technologies to Accurately Measure Patient Treatment Progress to Quickly Refine Treatment Strategies

  • Ben Kostiuk Director, Life Science Partnerships, Crohn's & Colitis Foundation of America

Synopsis

• Implementing imaging technologies to track therapy outcomes for precision surveillance

• Enhancing diagnostic imaging for precision treatment recalibration

• Integrating imaging biomarkers into comprehensive monitoring frameworks

4:30 pm Chair’s Closing Remarks

  • Mark Osterman Vice President, Early Differentiation and Pipeline for Immunology, Cardiovascular, and Neuroscience, Bristol Myers Squibb

4:40 pm End of Pre-Conference Focus Day